Tissue-Specific Knockout of the Insulin Receptor in Pancreatic β Cells Creates an Insulin Secretory Defect Similar to that in Type 2 Diabetes  by Kulkarni, Rohit N et al.
Cell, Vol. 96, 329±339, February 5, 1999, Copyright 1999 by Cell Press
Tissue-Specific Knockout of the Insulin Receptor
in Pancreatic b Cells Creates an Insulin Secretory
Defect Similar to that in Type 2 Diabetes
1991; Polonsky, 1995). Although insulin has been sug-
gested to regulate its own secretion and recently shown
to regulate expression of some genes in the b cell, the
role of insulin action in the b cell remains controversial
(Elahi et al., 1982; Argoud et al., 1987; Ammon et al.,
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Recently we have used the Cre-loxP system to pro-Harvard Medical School
Boston, Massachusetts 02215 duce a muscle-specific knockout of the insulin receptor
(Gu et al., 1994; BruÈ ning et al., 1998). In the present²Department of Molecular Physiology and Biophysics
Vanderbilt University School of Medicine study, we have directly assessed the role of functional
insulin receptors in the pancreatic b cell in vivo usingNashville, Tennessee 37232
the same strategy. We demonstrate that expression of
Cre using a b cell±specific rat insulin promoter results
in efficient recombination of a loxP-containing insulinSummary
receptor gene in the b cells. Mice lacking the b cell
insulin receptor show a loss of first-phase insulin secre-Dysfunction of the pancreatic b cell is an important
defect in the pathogenesis of type 2 diabetes, although tion in response to glucose, but not to arginine, similar
to that observed in humans with type 2 diabetes. Theseits exact relationship to the insulin resistance is un-
clear. To determine whether insulin signaling has a mice also show a progressively impaired glucose toler-
ance over 6 months. Thus, this model not only providesfunctional role in the b cell we have used the Cre-loxP
system to specifically inactivate the insulin receptor direct evidence for a functional role of the insulin recep-
tor in the pancreatic b cell, but also suggests that insulingene in the b cells. The resultant mice exhibit a selec-
tive loss of insulin secretion in response to glucose resistance at the b cell may contribute to alterations in
insulin secretion in type 2 diabetes, thereby creating aand a progressive impairment of glucose tolerance.
These data indicate an important functional role for the unifying hypothesis for development of this disease.
insulin receptor in glucose sensing by the pancreatic b
cell and suggest that defects in insulin signaling at Results
the level of the b cell may contribute to the observed
alterations in insulin secretion in type 2 diabetes. Creation of the IRlox and the b Cell±Specific
Insulin Receptor Knockout MiceIntroduction
Insulin receptors are expressed in most vertebrate tis-
sues. To specifically study the functional role of theType 2 diabetes is a genetically determined metabolic
insulin receptor in islet b cells, we utilized the techniquedisorder, affecting over 100 million people worldwide
of conditional gene inactivation using Cre-loxP medi-(Warram et al., 1990). The pathogenesis of type 2 diabe-
ated recombination (Gu et al., 1994; Kuhn et al., 1995;tes is characterized both by insulin resistance in muscle,
Metzger et al., 1995; Tsien et al., 1996). To achieve thisfat, and liver and a relative failure of the pancreatic b
goal a targeting vector was constructed using the mousecell (Martin et al., 1992; Lillioja et al., 1993; Kahn, 1994).
insulin receptor gene in which a selection cassetteDespite extensive study, no unifying hypothesis exists
flanked by loxP sites was introduced upstream of exonto explain these defects.
4 with a third loxP site downstream of exon 4. FollowingAt a molecular level, multiple alterations in the insulin
transfection of embryonic stem cells, clones expressingaction cascade have been shown to contribute to the
the homologous recombinants were transiently trans-insulin resistance, including downregulation of the re-
fected with a plasmid containing Cre cDNA to removeceptor, a decrease in receptor kinase activity, decreases
the selection cassette (Wurst and Joyner, 1993; BruÈ ningin phosphorylation of receptor substrates, and defects
et al., 1998), and the resultant clones heterozygous forin glucose transporter translocation (Caro et al., 1987;
the IRlox allele were injected into mouse blastocysts toReaven, 1988; Kahn, 1994; Olefsky and Nolan, 1995;
generate a chimeric mouse carrying an insulin receptorKerouz et al., 1997). The regulation of insulin secretion
allele with loxP sites flanking exon 4 (Figure 1a). Thesefrom the b cell is complex, and the molecular defects
chimeric mice were bred with C57BL/6J mice to produceunderlying the relative failure of the b cell in type 2
heterozygous IRlox animals. In the presence of Cre re-diabetes are still unclear. One of the characteristic fea-
combinase, exon 4 of the IRlox allele would be deleted,tures of this defect is a failure of the b cell to respond
thereby causing a frameshift mutation and an immediateto a glucose stimulus while retaining its response to
stop of translation. The final product of this gene, if oneother secretagogues such as amino acids (Porte, Jr.,
exists at all, would represent a 308 amino acid fragment
of the N terminus of the insulin receptor a subunit, lack-
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joslab.harvard.edu).
and kinase domains.§ These authors contributed equally to this work.
Rip-Cre transgenic mice carrying the Cre transgene‖ Present address: Klinik II und Poliklinik fuÈ r Innere Medizin, Universi-
taÈ t zu KoÈ ln, D-50924 Cologne, Germany. were created using a 668 bp b cell±specific rat insulin
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Figure 1. Targeting Vector and Analysis of
Cre Expression in Pancreatic Islets
(a) Targeting vector for the IRlox allele. The
restriction map is shown of a portion of the
mouse insulin receptor gene used in the cre-
ation of the targeting vector. A neomycin-her-
pes simplex virus-thymidine kinase selection
cassette was introduced flanked by loxP sites
upstream of exon 4. An additional loxP site
was introduced 80 bp downstream of exon 4.
Arrows indicate selection of the homologous
recombinants and Cre-mediated deletion of
exon 4. Primers P1 and P2 were used in PCR
analysis to confirm the type II deletion. Re-
striction sites are indicated as follows: K,
KpnI; N, NotI; S, SpeI; Xb, XbaI; Xh, XhoI.
(b) Immunofluorescent histochemical analy-
sis of pancreas sections of a Cre-expressing
mouse. Two individual islets are shown with
Cre (red) staining localized to the insulin-pro-
ducing b cell (green).
2 promoter. These mice exhibited specific Cre expres- Assessment of the Effect of the Rip-Cre
Transgene on the IRlox Allelesion in insulin-producing b cells, but not in non±b cells or
acinar cells by double label immunofluorescence (Figure To evaluate the efficiency of recombination of the IRlox
allele in the islet triggered by Cre expression, we used1b). Furthermore, the ability of the Cre to induce pancre-
atic-specific inactivation was demonstrated when these a PCR strategy using DNA prepared from islets isolated
from bIRKO and IRlox mice. A single 300 bp band wasfounder mice were bred with mice carrying a floxed
glucokinase gene (Postic et al., 1999). observed in islets from homozygous IRlox mice, indicat-
ing the presence of exon 4 (Figure 2a). In contrast, usingTo create b cell±specific insulin receptor knockout
(bIRKO) mice, the IRlox mice carrying the Cre transgene DNA prepared from islets from bIRKO mice, the major
product was 220 bp, indicating the deletion of exon 4were bred with the IRlox heterozygous mice. The geno-
type of the bIRKO mice (i.e., animals carrying the Cre and splicing of exons 3 and 5 as would occur following
Cre-mediated recombination. A faint 300 bp band wastransgene and homozygous for the IRlox allele) was con-
firmed by PCR analysis of tail DNA. This breeding also observed in addition to the 220 bp product in the sample
lane with 25 islets in the bIRKO mice, indicating thegenerated three littermate control groupsÐnamely, ho-
mozygous IRlox mice (IRlox) to rule out the effect of presence of some unrecombined insulin receptor gene.
This can be accounted for by the fact that b cells makeintroduction of loxP sites in the insulin receptor gene,
mice carrying only the Cre transgene on a rat insulin up approximately 80%±85% of islet cells. Thus, DNA
prepared from islets is a mixture of b cell DNA, DNApromoter (Rip-Cre) to rule out any effect of Cre expres-
sion on b cell function, and wild-type (WT) controls. All from non±b islet cells (e.g., a cells, d cells, and PP cells),
as well as some integrated vascular tissues that shouldanimals were born normally at the expected Mende-
lian frequency, and no significant differences in body not exhibit a recombination event. In order to confirm
this, we carried out IRlox PCR analysis of DNA preparedweights were observed between newborn bIRKO mice
and homozygous IRlox, Rip-Cre, and WT littermates up from pure b cells, as well as non±b cells, obtained from
dispersed islets using flow cytometry. A single 220 bpto 6 months. bIRKO mice were fertile and produced
normal-sized litters, and their development was not dif- band was obtained in the lane loaded with b cells from
bIRKO islets, while a higher molecular weight band offerent from that observed in the control littermates.
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Figure 2. Assessment of Insulin Receptor Recombination and Expression in the bIRKO Mice
(a) Schematic representation of the IRlox allele (upper panel) showing the position of the different primers used in the PCR analysis. The
knockout allele is shown below indicating the deletion of exon 4 in the event of recombination of the insulin receptor gene. The lower panel
shows a representative PCR analysis of DNA prepared from 5, 10, and 25 islets from liver and skeletal muscle of bIRKO and homozygous
IRlox mice. The smaller 220 bp band is observed only in islets from bIRKO mice.
(b) RT-PCR analysis on RNA prepared from islets from one homozygous IRlox and two different bIRKO mice. The RT reaction was carried
out as described in methods using 1 mg of total RNA. A high-molecular-weight band (480 bp) was observed in all lanes, while a smaller band
of 220 bp was observed only in the lanes representing the bIRKO mice, suggesting a recombination event.
(c) PCR analysis of DNA prepared from pure b and non±b cells obtained from flow cytometry using islets isolated from bIRKO and homozygous
IRlox mice. The smaller 220 bp band was observed in b cells from bIRKO islets (lane 3), but not in non±b cells from bIRKO islets (lane 2) or
b cells prepared from IRlox islets (lane 1).
(d) Western blot analysis of skeletal muscle, liver, heart, and brain of WT (lane 1), IRlox (lane 2), Cre (lane 3), and bIRKO (lane 4) mice. Tissues
were immunoprecipitated and subjected to Western blot analysis using an anti-insulin receptor antibody. No significant differences were
observed in expression level in three mice from each of the four different genotypes.
300 bp was evident only in the lanes with non±b cells skeletal muscle, liver, and heart, was assessed by immu-
noblotting and was unaltered (Figure 2d). Thus, the intro-from bIRKO islets and b cells from IRlox islets (Figure
2c). These data suggest a complete recombination of duction of the loxP sites in the insulin receptor gene did
not interfere with receptor expression, and knockout ofthe insulin receptor gene specifically in the b cells ob-
tained from bIRKO islets. the insulin receptor was specific to the b cell in bIRKO
mice.Within the islet itself, very little is known about insulin
receptor expression in non±b cells versus b cells. To
obtain some estimate of this and to confirm the recombi-
Physiological Effects of b Cell±Specific Disruptionnation event in the b cells, we also carried out RT-PCR
of the Insulin Receptorusing 1 mg of total RNA prepared from islets isolated
Effects on Insulin and Glucose Levelsfrom the homozygous IRlox and bIRKO mice. A 480 bp
To begin to assess the effect of the b cell insulin receptorPCR product was present in samples from both IRlox
knockout on glucose homeostasis, glucose and insulinand bIRKO mice, indicating the presence of normal insu-
levels were measured in the fasted and random-fedlin receptor mRNA. In addition, a smaller product of 220
states. No significant differences were observed inbp was present only in the bIRKO sample, confirming
blood glucose levels in either male or female bIRKOthat recombination had occurred (Figure 2b). Although
mice as compared to those in the control groups atPCR is not quantitative, the relative expression of intact
either 2 months (data not shown) or 6 months of agereceptor RNA in islet extracts of bIRKO mice as com-
(Figures 3a±3d). The fasting insulin levels in the malespared with the high level of recombination of DNA in
were also comparable between the four groups of micethese same islets suggests that most of the insulin re-
at 2 months of age, but there appeared to be a mildceptor mRNA in the islet extract is derived from non±b
islet cells which have not undergone the recombination degree of hyperinsulinemia in the females (0.9 6 0.08
in bIRKO vs. 0.56 6 0.09 in WT; p , 0.05, n 5 7±17). Aevent.
The expression of the insulin receptor in other tissues similar pattern was observed in females at 6 months of
age (Figure 3f). By 6 months of age, fasting insulin levelsof the mouse, including non±insulin-responsive tissues
like brain and insulin-responsive tissues such as the had also increased in all groups of male mice and were
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Figure 3. bIRKO Mice Exhibit Normal Blood Glucose Levels and Mildly Elevated Fasting Plasma Insulin Concentrations at 6 Months of Age
Blood glucose from overnight (14 hr) fasted (a and b) and random-fed (c and d) 6-month-old WT (filled circles), homozygous IRlox (filled
triangles), Cre (filled squares), and bIRKO (filled diamonds) male (a and c) and female (b and d) mice. A scatter plot is shown (n 5 10±24). No
significant differences were observed between the four groups.
Plasma insulin concentrations were determined from 14 hr fasted 6-month-old male (e) and female (f) mice. WT (stippled bars), IRlox (hatched
bars), Cre (bars with horizontal stripes), and bIRKO (cross-hatched bars). Each bar represents the mean 6 SEM of n 5 10±24 mice. **, p ,
0.01; *, p , 0.05; bIRKO vs. WT or IRlox or Cre.
almost 2-fold higher in the male bIRKO mice as com- and 4d). Thus, the bIRKO mice, but not the controls,
show a major loss of acute first-phase insulin releasepared with the IRlox and WT controls (Figure 3e). No
differences were observed in fasting insulin levels in specific to glucose while maintaining the response to
arginine, suggesting that a functional insulin receptoreither the IRlox or Rip-Cre control mice.
bIRKO Mice Exhibit Decreased Acute and/or insulin response is requisite for a normal glucose-
stimulated secretory response by the b cell.Insulin Release to Glucose
To further evaluate the effect of tissue-specific insulin bIRKO Mice Exhibit Impaired Glucose Tolerance
To assess the impact of altered first-phase insulin re-receptor deletion on the pancreatic b cell function, insu-
lin release was measured in response to stimulation with lease on the ability of the mice to dispose of a glucose
load, glucose disposal was assessed by intraperitonealthe two major nutrient secretagogues of insulinÐglucose
and arginine. In both male and female controls, a 3- to (IP) injection of glucose (2 g/kg body weight) following
an overnight fast. As noted above, at all ages up to 64-fold increase in insulin secretion was observed 2 min
after IP glucose injection, and the levels remained higher months, fasting glucose levels were the same in the
bIRKO mice as in the controls. Upon glucose challenge,than baseline values for up to 30 min, indicating a sec-
ond-phase response (Figures 4a and 4b). In the bIRKO however, both male and female bIRKO mice showed
significantly higher glucose levels than the controls,mice, the acute first-phase insulin secretory response
to glucose was reduced by 85% in the females and even at 2 months of age (Figures 5a and 5b). The glucose
tolerance continued to worsen in the bIRKO mice withvirtually absent in the males. The insulin levels, however,
did gradually rise after the glucose challenge, and by age, and by 6 months, glucose levels were more than
twice as high in the bIRKO mice as controls following30 min they were not significantly different between the
groups, suggesting some retention of second-phase in- IP glucose challenge in both males and females (Figures
5c±5f). Insulin levels during the GTT were significantlysulin secretion in the bIRKO mice.
Arginine stimulates acute insulin release by mecha- lower at all time points in 4-month-old female bIRKO
mice compared with IRlox controls, providing furthernisms that are independent of those used by glucose,
although the final common pathways of secretion are evidence for a secretory defect in response to glucose
(15 min, 1.1 6 0.2 vs. 2.1 6 0.2; 30 min, 1.5 6 0.2 vs.the same (Weinhaus et al., 1997). Therefore, to deter-
mine the level of defect in glucose-stimulated insulin 2.6 6 0.3; 60 min, 1.6 6 0.12 vs. 2.1 6 0.18; and 120
min, 1.1 6 0.5 vs. 2.0 6 0.3, all p , 0.05, n 5 4±5). Thus,release, mice were also given an acute arginine chal-
lenge. In contrast to the response to glucose, in both the bIRKO mice exhibited an age-dependent progres-
sive impairment in their ability to dispose of a glucosethe bIRKO and control mice, there was a 5- to 6-fold
acute insulin release in response to arginine (Figures 4c load.
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Figure 4. bIRKO Mice Exhibit a Selective Loss of Acute Phase Insulin Secretion in Response to Glucose but Not to Arginine
Glucose (3 g/kg body weight) was injected intraperitonally in 3- to 4-month-old male (a) and female (b) WT (filled squares), homozygous IRlox
(open triangles), and bIRKO (filled circles) mice. Blood samples were collected at the indicated time intervals from tail vein samples for insulin
RIA. A significantly blunted response was observed in male and female bIRKO mice as compared with controls. Values are means 6 SEM,
(n 5 3±14). ***, p , 0.001; **, p , 0.01; *, p , 0.05; bIRKO vs. WT or IRlox. Arginine-stimulated acute phase insulin secretion was tested by
IP injection of L-arginine (3 mg/g body weight). No significant differences were observed between the groups in male (c) or female (d) mice.
Values are means 6 SEM (n 5 7±8).
Morphology and Insulin Content of the Pancreas cent staining of paraffin sections of pancreas isolated
from bIRKO and IRlox mice using a Glut2 antibody. Al-To evaluate whether the alterations in islet function were
associated with any changes in morphology, we carried though the islets were somewhat smaller in the 4-month-
old bIRKO mice, the distribution of Glut2 appeared toout immunohistochemical studies on the pancreas. Analy-
sis of sections of pancreas using a cocktail of antibodies be comparable with that in the controls (Figure 7b). Islets
isolated from ob/ob mice, on the other hand, showedto non±b cell hormones showed no apparent differences
in islet size or in the ratio of b to non±b cells at 2 months barely detectable Glut2 in the b cells, consistent with
previous reports (Thorens et al., 1992). Assessment ofof age (Figure 6a). Assessment of insulin content in the
pancreas showed comparable levels at 2 months of age b cell morphology was also carried out by electron mi-
croscopy and revealed well-preserved architecture ofconsistent with the islet morphology (Figure 6b). How-
ever, in 4-month-old bIRKO mice, there appeared to the cells with no apparent differences in the cell mem-
brane, endoplasmic reticulum, Golgi, or electron-densebe a modest decrease (z20%±40%) in islet size when
compared with controls (Figure 6a). Insulin content at insulin-containing granules within the b cells in the
bIRKO versus IRlox mice (Figure 7a).this age also showed a small increase in control mice
as compared with 2 month levels, while the content in
the bIRKO mice remained unchanged. This resulted in Discussion
35% lower insulin content in 4-month-old bIRKO mice
as compared with controls (Figure 6b). Thus, the de- Glucose homeostasis in mammals is tightly controlled
by a balanced interaction between peripheral tissue sen-crease in first phase insulin secretion in the bIRKO mice
cannot be explained simply by a decrease in islet size sitivity to insulin and insulin secretion. In both humans
and rodents, decreased action of insulin in peripheralor insulin content.
Since one of the rate-limiting steps for glucose sens- tissues (i.e., insulin resistance) is a central feature of
several common pathological states, including obesity,ing is entry into the b cell, we carried out immunofluores-
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Figure 5. bIRKO Mice Demonstrate a Progressively Impaired Glucose Tolerance
The ability to handle a glucose load was assessed by carrying out a glucose tolerance test (2 g/kg body weight IP) at 2, 4, and 6 months of
age in WT (filled squares), IRlox (open triangles), Cre (open diamonds), and bIRKO (filled circles) male (a, c, and e) and female (b, d, and f)
mice. An age-dependent glucose intolerance was observed in both male and female mice. Results are expressed as mean 6 SEM (n 5 10±25).
***, p , 0.001; **, p , 0.01; *, p , 0.05; bIRKO vs. WT or IRlox or Cre. #, p , 0.05; bIRKO vs. WT or Cre.
hypertension, and glucocorticoid excess (Reaven, 1988; b cell (Fajans, 1989; Froguel et al., 1992; Polonsky, 1995).
In typical type 2 diabetes, however, the relationship be-Kahn, 1994). In humans destined to develop type 2 dia-
betes, insulin resistance can often be detected years tween plasma glucose and insulin level is complex. The
relationship has been likened to a ªbell-shapedº curveprior to onset of clinical disease (Warram et al., 1990;
Lillioja et al., 1993). In these pre±type 2 diabetic individu- in which insulin resistance and mildly impaired glucose
tolerance are associated with increasing insulin levelsals, the b cell is capable of secreting adequate and even
increased amounts of insulin to overcome the defect until glucose desensitization supervenes and further in-
creases in the glucose concentration are associatedin insulin action and maintain euglycemia. Ultimately,
however, this balance between insulin resistance and with a progressive decline in insulin secretion (Bogardus
et al., 1984; DeFronzo, 1988). Other mechanisms postu-insulin secretion is broken, and the full phenotype of
type 2 diabetes with defects in b cell function develops lated to contribute to an abnormal b cell function in-
clude an abnormal oscillatory pattern of insulin secretion(DeFronzo, 1988; Leahy et al., 1992).
Several factors have been postulated to contribute to (O'Rahilly et al., 1988; O'Meara et al., 1993), an increased
secretion of proinsulin and proinsulin-like productsthe relative secretory dysfunction of the pancreatic b
cell in type 2 diabetes. Among these, loss of first-phase (Reaven et al., 1993; Hales, 1994), and an inability of
glucose to appropriately potentiate the effect of otherinsulin secretion in response to glucose is probably the
earliest detectable abnormality (Cerasi et al., 1972; Efen- insulin secretagogues like amino acids (McRae et al.,
1981; Porte, Jr., 1991; Polonsky, 1995). Thus, the precisedic et al., 1988; Polonsky, 1995; Poitout and Robertson,
1996). Although some studies have shown that tight nature of the b cell defect that leads to a relative insuffi-
ciency of insulin is still obscure, but it centers aroundmetabolic control can partially restore the secretory pro-
cess (Vague and Moulin, 1982), the underlying defect a failure of the b cell to respond appropriately to the
glucose.causing the selective loss of glucose response is not
known. A primary defect in early insulin secretion can We and others have successfully used the technique
of Cre-loxP mediated recombination to inactivate genesalso lead to hyperglycemia (Nesher et al., 1987; Efendic
et al., 1988; Turner et al., 1988; Temple et al., 1989). in mice in a tissue-specific fashion (Gu et al., 1994;
Metzger et al., 1995; Tsien et al., 1996; BruÈ ning et al.,Indeed, this occurs in individuals with maturity onset
diabetes of the young (MODY) who have genetic defects 1998). In the present study, we have used this method
to delete the insulin receptor in the pancreatic b cell toin either transcription factors important for b cell devel-
opment and function or defects in the gene for glucoki- specifically address the question whether disruption of
insulin signaling in the b cell could contribute to annase, a key enzyme involved in glucorecognition by the
Insulin Receptor Knockout in Pancreatic b Cells
335
Figure 6. Islet Size and Pancreatic Insulin Content in bIRKO Mice
(a) Immunostaining for non±b cell hormones was carried out in pancreatic sections from 2-month-old and 4-month-old control (WT and IRlox)
and bIRKO mice using a cocktail of antibodies to glucagon, somatostatin, and pancreatic polypeptide. Representative sections are shown
from a control and bIRKO mouse.
(b) Pancreatic insulin content was measured in acid-ethanol extracts from control (CON) and bIRKO mice by RIA. Values are expressed as
means 6 SEM in pg/mg pancreas, (n 5 3±5). **, p , 0.01; bIRKO vs. Control.
alteration in islet function. To achieve b cell±specific restricted by the limited amount of protein or number
of isolated b cells that can be obtained, as well as theinactivation we have used a Rip-Cre transgene. The
Rip-2 promoter is exclusively expressed in the islet b difficulty in assessing insulin action in a tissue secreting
large amounts of the hormone. Several in vivo and incells from embryonic day 9 onward (Pictet and Rutter,
1972). Immunohistochemistry indicates specific colo- vitro studies have attempted to address the question
whether insulin secreted from the islets regulates itscalization of Cre with insulin in islet b cells from Rip-
Cre mice, and assessment of the recombination event own synthesis and/or secretion with conflicting results
(Iversen and Miles, 1971; Elahi et al., 1982; Argoud etusing DNA from pure b cells from bIRKO mice showed
evidence consistent with complete recombination in the al., 1987; Ammon et al., 1991). Likewise, the presence
of insulin receptors in pancreatic b cells has been diffi-b cell. This is consistent with studies in which the Rip-
Cre transgene has been used to specifically inactivate cult to substantiate by either direct binding or autoradi-
ography (Verspohl and Ammon, 1980; Patel et al., 1982;the glucokinase gene in b cells, but not in liver (Postic
et al., 1999). The absence of any alteration in the insulin Van Schravendijk et al., 1985). On the other hand, Lei-
biger et al. (1998) have demonstrated that insulin se-receptor expression in several other tissues confirms
the overall specificity of the Cre-loxP system in these creted by the b cell may positively regulate insulin bio-
synthesis in hamster insulinoma cells in which insulingene deletion experiments.
The bIRKO mice provide the first in vivo model demon- receptors are overexpressed. b cells do appear to con-
tain IGF-1 receptors, and IGF-1 has been shown to nega-strating the consequences of a lack of functional insulin
receptors in the islet b cell. These mice show a selective tively regulate insulin secretion (Van Schravendijk et al.,
1987; Leahy and Vandekerkhove, 1990).loss of glucose-stimulated early insulin release and an
age-dependent inability to handle a glucose challenge. Data supporting the presence of some components
of the insulin signaling pathway in normal islet b cellsAlthough defects in the insulin action cascade have
been demonstrated in tissues such as the skeletal mus- have been provided by recent studies demonstrating
expression of insulin receptor mRNA and insulin recep-cle and the liver, studies on islet b cells have been
Cell
336
Figure 7. Electron Microscopy and Glut2 Staining in Islets from bIRKO Mice
(a) Electron microscopic examination of b cells in isolated islets was carried out as described. Representative sections show b cells with
insulin-containing granules from a control (IRlox) and bIRKO mouse. Magnification, 19,8003.
(b) Immunostaining for the glucose transporter Glut2 was carried out in pancreatic sections from 4-month-old male bIRKO, IRlox, and ob/ob
mice using a Glut2 antibody.
tor substrate-1 (IRS-1) in islet b cells and clonal b cell of type 2 diabetes where there is a selective loss of
acute phase insulin secretion in response to glucoselines (Velloso et al., 1995; Harbeck et al., 1996; Leibiger
et al., 1998). Furthermore, disruption of the IRS-2 gene while maintaining the response to other secretagogues,
including arginine and tolbutamide (Pfeifer et al., 1982;results in hypoplastic islets and b cell failure with devel-
opment of hyperglycemia and hyperinsulinemia at 1 to Trent et al., 1984). Thus, the loss of the glucose-stimu-
lated acute-phase insulin response may be due to insulin2 months of age (Withers et al., 1998). On the other hand,
mice with disruption of the IRS-1 gene and mice double resistance at the level of the b cell itself.
Studies in some animal models of diabetes relate theheterozygous for null alleles in the insulin receptor and
IRS-1 show elevated plasma insulin levels and b cell loss of the acute phase secretion to reduced Glut2 levels
in the b cells (Unger, 1991; Thorens et al., 1992). In thehyperplasia (Araki et al., 1994; Tamemoto et al., 1994;
BruÈ ning et al., 1997). In the latter case, 40%±50% of the bIRKO mice, however, Glut2 staining was similar to that
in the IRlox controls. Likewise, there was no differencemice become overtly diabetic by 4±6 months of age
(BruÈ ning et al., 1997). Thus, these studies indicate in b cell morphology at the electron microscope level,
and only a very modest decrease in islet size in olderinvolvement of IRS proteins both in the growth and se-
cretory function of the islets, but they do not address bIRKO mice. These data suggest that the altered glu-
cose sensing is not the result of a developmental abnor-the role of the insulin receptor itself.
In the present study, we examined the insulin secre- mality, but rather the result of alterations in the intracel-
lular mechanisms of glucose sensing or the specifiction pattern in b cell insulin receptor knockout (bIRKO)
mice using nutrient stimulants commonly employed in secretory machinery involved in glucose-stimulated in-
sulin release. It is also possible that there is an alterationassessing the first-phase insulin secretion in type 2 dia-
betes (Pfeifer et al., 1982). When compared to controls, in proinsulin to insulin conversion or in the use of consti-
tutive versus regulated pathways of insulin secretion.bIRKO mice showed a near complete loss of first-phase
insulin release in response to glucose, but not to argi- The decreased insulin secretion observed in the
bIRKO mouse contrasts the increased insulin secretionnine, even by 3 months of age when fasting and fed
glucose levels remain identical to those of control ani- usually observed in humans with mutations in the insulin
receptor gene (Flier et al., 1975; Taylor, 1992). This maymals. This finding is similar to humans early in the course
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flanking exon 4 as previously described (BruÈ ning et al., 1998).be due to several factors. First, the loss of insulin signal-
Transgenic mice expressing Cre recombinase under the control ofing in the peripheral tissues in the humans with muta-
a b cell±specific rat insulin 2 promoter (Rip-Cre mice) were createdtions results in severe peripheral insulin resistance that
using a fusion gene construct made up of 668 bp of the rat insulin
may mask the abnormal function of the b cells. Second, 2 promoter, nuclear localization sequence (nls)-modified Cre, and
most patients with mutations continue to synthesize a 2.1 kb fragment of the human growth hormone gene (hGH) con-
taining 5 exons and 4 introns (Postic et al., 1999) and were hybridssome receptor protein that may exert a dominant nega-
derived from 129sv, C57Bl/6, and DBA-2 strains. Expression of thetive effect or signal in some minor fashion. Finally, of
Rip-Cre transgene was limited to pancreatic b cells by both RT-course, there may be differences between species in
PCR analysis and the use of Cre-activatable LacZ reporter mice.terms of the role of insulin receptors in b cell function.
Immunohistochemistry indicated detectable Cre in at least 82% of
Whatever the reason, the bIRKO mouse is the only model pancreatic b cells (Figure 1b). All animals were housed in specific
of selective loss of insulin receptors in the b cell that pathogen-free facilities and maintained on a 12 hr light/dark cycle
enables the study of insulin signaling in these cells with- and fed a standard rodent chow (Purina Mills, St Louis, MO).
Genotyping was performed on DNA isolated from the tails of 2-out other confounding effects, since mice with a global
to 4-week-old mice by PCR. The 59 and 39 primers for the Creknockout of the insulin receptor die within a few days
transgene were 59-ATGTCCAATTTACTGACCG-39 and 59-CGCCGCdue to diabetic ketoacidosis (Accili et al., 1996; Joshi
ATAACCAGTGAAAC-39 and for the IRlox gene were 59-GATGTGCAC
et al., 1996). CCCATGTCTG-39 and 59-CTGAATAGCTGAGACCACAG-39.
As a result of the reduced first-phase insulin secretion,
bIRKO mice show impaired glucose tolerance as early Assessment of Recombination in Islet DNA and RNA
as 2 months of age. The intolerance is progressive with Animals were anaesthetized with sodium amobarbital (Eli Lilly, 75
age, although fasting and random-fed blood glucose mg/kg), and islets were isolated by the intraductal collagenase di-
gestion method (Kulkarni et al., 1997). Hand-picked islets werelevels in these mice are not elevated even at 6 months.
washed 23 in PBS and once with diethyl pyrocarbonate-treatedThe exact mechanism underlying this finding will require
water, then placed in 0.5 ml PCR tubes and denatured (958C, 20further experiments, but several possibilities exist. Glu-
min). The released DNA was subjected to PCR in a total volume ofcose may regulate the function of the b cell insulin recep-
50 ml using three primers. The first one 59 to the 59loxP site (P3)
tor either by acting on proteins in the insulin receptor was located in exon 3 with the sequence 59-CTGTTCGGAACCTGAT
signaling pathway or by stimulating the release of insu- GAC-39, while the second primer (P1) was located in exon 4±59-
lin, which in turn acts on its own receptor in an autocrine TCTATCATGTGATCAATGATTC-39. The third primer in exon 5 (P2)
was located at the 59 end of the loxP site downstream of exon 4±59-manner (Rothenberg et al., 1995). HIT insulinoma cells
ATACCAGAGCATAGGAG-39. The PCR conditions used included 25transiently transfected with several mutant insulin re-
cycles of 958C for 5 min, 938C for 30 s, 558C for 30 s, and 728C forsponsive promoter constructs demonstrate a response
1 min followed by a single cycle of 728C for 5 min. Thirty milliliters
to glucose-stimulated insulin release that involves the of the PCR reaction was run on a 1.4% agarose gel and electropho-
phosphatidylinositol 3-kinase and p70 S6 kinase path- resed for 2 hr at 80 V. A 300 bp amplified product indicated an intact
way known to be activated by insulin (Leibiger et al., exon 4, while a 220 bp product suggested the presence of Cre-
mediated recombination. For some experiments DNA was prepared1998). Indeed, it is possible the reduced glucose-stimu-
from pure b cells obtained by flow cytometry (Josefsen et al., 1996).lated insulin release and low insulin content in bIRKO
For RNA, the RT reaction was carried out using a RT-PCR kitmice are in part the result of an alteration at the level
(Pharmacia Biotech) with 1 mg total RNA, first strand mix, and aof insulin-regulated gene transcription.
random hexamer primer. After incubation at 378C for 1 hr, the sam-
Taken together, the data in the present study demon- ples were quenched on ice, and 3 ml of the RT reaction was used
strate that a mouse with a specific deletion of the b cell in the PCR. The two primers used in the PCR, RT2 (59-GTGATACCAG
insulin receptor exhibits a selective loss of the acute AGCATAGGAG-39) and RT3 (59-CTGTTCGGAACCTGATGAC-39),
were located in exon 5 and exon 3, respectively. A 480 bp amplifiedphase secretion in response to glucose and progres-
PCR product indicated an intact insulin receptor, while a 220 bpsively impaired glucose tolerance. These findings pro-
product indicated Cre-mediated recombination and deletion ofvide direct evidence of a functional role for the insulin
exon 4.
receptor in the islet b cell in the maintenance of glucose
homeostasis and suggest that insulin resistance at the
Analysis of Insulin Receptor Expression by Western Blottinglevel of the b cell may be a significant factor in the Animals were anesthetized, and skeletal muscle, liver, heart, and
development of a loss of glucose-stimulated insulin se- brain were dissected and frozen immediately. Protein extracts pre-
cretion by the b cells. Thus, a novel unifying hypothesis pared from these tissues were subjected to immunoprecipitation
using insulin receptor-specific antisera followed by Western blotcan be formulated for type 2 diabetes in which insulin
analysis with the same antibody using standard protocols (Araki etresistance at the b cell level coupled with insulin resis-
al., 1994).tance at the periphery could result in the classical patho-
physiological findings of this disease. While it is unlikely
Glucose Tolerance Tests and Insulin Releasethat in humans this is due to a genetic alteration in the
Mice were fasted overnight for 14 hr followed by intraperitonealinsulin receptor, combinations of acquired and genetic
(IP) glucose injection (2 g/kg body weight). Whole venous blood
alterations in the receptor and post-receptor signaling obtained from the tail vein at 0, 15, 30, 60, and 120 min after the
steps could provide a mechanism for this complex dis- injection. Blood glucose was measured using an automatic gluco-
ease syndrome. meter (One Touch, Lifescan, Daly).
For insulin release, glucose (3 g/kg body weight) or L-arginine (10
mM/l in 0.2 M PBS) (Gillies and Mandel, 1990) was injected IP, andExperimental Procedures
venous blood was collected at 0, 2, 5, 15, and 30 min in chilled
heparinized tubes, immediately centrifuged, and the plasma storedAnimals and Genotyping
at 2208C. Insulin levels were measured with a radioimmunoassayIRlox mice derived from 129sv and C57Bl/6 were created by homolo-
gous recombination using an insulin receptor gene with loxP sites kit with a rat insulin standard (Linco, St. Louis, MO). Pancreatic
Cell
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insulin was measured by RIA in acid ethanol extracts of whole pan- insulin receptor knockout exhibits features of the metabolic syn-
drome of NIDDM without altering glucose tolerance. Mol. Cell 2,creas.
559±569.
Caro, J.F., Sinha, M.K., Raju, S.M., Ittoop, O., Pories, W.J., Flickinger,Immunohistochemical Analysis and Electron Microscopy
E.G., Meelheim, D., and Dohm, G.L. (1987). Insulin receptor kinaseSections of pancreas were stained for non±b cell hormones using
in human skeletal muscle from obese subjects with and withouta cocktail of antibodies to glucagon, somatostatin, and pancreatic
non-insulin-dependent diabetes. J. Clin. Invest. 79, 1330±1337.polypeptide (Bonner-Weir et al., 1989). Immunostaining for Cre was
carried out using a polyclonal anti-Cre antibody (Jetton and Magnu- Cerasi, E., Luft, R., and Efendic, S. (1972). Decreased sensitivity of
son, 1992). Staining for Glut2 was carried out on paraffin sections of the pancreatic beta cells to glucose in prediabetic and diabetic
pancreata with anti-mouse Glut2 polyclonal antibody (final dilution subjects. A glucose dose-response study. Diabetes 21, 224±234.
1:1000; gift from B. Thorens) and examined under a confocal micro- DeFronzo, R.A. (1988). Lilly Lecture 1987. The triumvirate B-cell,
scope (Zeiss, Germany) at an emission wavelength of 568 nm. For muscle, liver: a collusion responsible for NIDDM. Diabetes 37,
electron microscopy, islets were placed in 2% glutaraldehyde, 0.1 667±687.
M phosphate buffer (pH 7.4) overnight at 48C, then washed and
Efendic, S., Grill, V., Luft, R., and Wajngot, A. (1988). Low insulin
fixed in 2% OsO4. Sections (400±500 AÊ ) were stained with saturated response: a marker of prediabetes. Adv. Exp. Med. Biol. 246,
uranyl acetate and lead citrate before being examined under a Phil-
167±174.
lips 301 Transmission Electron Microscope.
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J.D., Blix, P.M., Rubenstein, A.H., Unger, R.H., and Andres, R. (1982).
Statistical Procedures Feedback inhibition of insulin secretion by insulin: relation to the
All values unless otherwise indicated are expressed as mean 6 SEM. hyperinsulinemia of obesity. N. Engl. J. Med. 306, 1196±1202.
Statistical analyses were carried out using a two-tailed student's
Fajans, S.S. (1989). Maturity-onset diabetes of the young (MODY).unpaired t test, and the null hypothesis was rejected at the 0.05
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